UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

~~SECURITIES AND EXCHANGE COMMISSION~~_________________

~~Washington,~~FORM ~~D.C. 20549~~6-K

~~Form 6-K~~_________________

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16 OR 15d-16~~

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41933

_________________

Haoxi Health Technology Limited

~~(Translation of registrant’s name into English)~~_________________

Room 801, Tower C, Floor 8, Building ~~103~~103Huizhongli, ~~Huizhongli,~~ Chaoyang ~~District~~DistrictBeijing, China+86-10-13311587976

Beijing, China

(Address of principal executive office)

~~Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.~~_________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~Entry~~Other ~~into Securities Purchase Agreement~~Events

~~On May~~Attached ~~18,~~hereto ~~2026,~~as ~~Haoxi~~Exhibit 99.1 ~~Health~~and ~~Technology~~Exhibit 99.2 ~~Limited~~is ~~(the~~a ~~“Company”)~~notice ~~entered~~of ~~into~~the aextraordinary ~~Securities~~general ~~Purchase~~meeting ~~Agreement~~ (the “~~Purchase Agreement~~Extraordinary General Meeting”) ~~with~~of ~~Mr.~~shareholders ~~Zhen Fan~~ (the “~~Purchaser~~Notice”), ~~the Company’s Chief Executive Officer~~ and ~~the~~a ~~chairman of~~proxy ~~the~~card ~~board of the directors~~ (the “~~Board~~Proxy Card”) , ~~pursuant to which the Company agreed to issue and sell to the Purchaser~~respectively, ~~and~~ ~~the Purchaser agreed to purchase from the Company, 40,000,000 Class B ordinary shares~~ of ~~the~~Haoxi ~~Company,~~Health ~~par~~Technology ~~value~~Limited ~~US$0.0025 per share~~ (the “~~Shares~~Company”), atrelating ~~a purchase price of US$0.018 per share, for an aggregate purchase price of US$720,000, subject~~ to the ~~terms~~Company’s ~~and~~Extraordinary ~~conditions~~General ~~set forth in the Purchase Agreement~~Meeting.

~~The purchase~~Where ~~price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The Company intends~~ to ~~use~~Find ~~the~~Additional ~~net proceeds from the sale of the Shares for working capital and general corporate purposes.~~Information

The ~~Shares~~ ~~are~~Company ~~being~~is ~~offered~~a ~~and~~foreign ~~sold~~private inissuer. ~~reliance~~As ~~upon exemptions from the registration requirements of the Securities Act of 1933~~such, ~~as amended (~~the ~~“Securities~~Notice ~~Act”),~~is ~~including~~not ~~Section~~subject ~~4(a)(2)~~to ofreview ~~the Securities Act~~ and~~/or~~ ~~Regulation~~comment Sby ~~promulgated thereunder. The Shares have not been registered under~~ the U.S. Securities ~~Act or any state securities laws~~ and ~~may~~Exchange ~~not~~Commission ~~be offered or sold in~~ (the ~~United States absent registration or an applicable exemption from registration requirements~~“SEC”).

~~The Purchase~~Shareholders ~~Agreement~~are ~~contains~~urged ~~customary~~to ~~representations,~~carefully ~~warranties,~~read ~~covenants~~the Notice, ~~closing~~because ~~conditions~~it ~~and~~contains ~~indemnification~~important ~~provisions~~information ofabout the Company and the ~~Purchaser.~~Extraordinary ~~The~~General ~~closing~~Meeting of ~~the~~Shareholders. ~~transaction~~Copies isof ~~subject~~Notice toand ~~the~~other ~~satisfaction~~documents filed or ~~waiver~~submitted ofby ~~customary~~the ~~closing~~Company ~~conditions~~will ~~set forth~~be inavailable at the ~~Purchase~~website ~~Agreement,~~maintained ~~including,~~by ~~among~~the ~~others,~~SEC ~~the~~at www.sec.gov. ~~delivery~~Shareholders may obtain a copy of such filings, free of charge, from the ~~purchase~~Company’s ~~price~~website at http://www.haoximedia.com/, or by ~~the~~writing ~~Purchaser~~to ~~and~~us ~~the~~at ~~issuance~~Room of801, ~~the Shares~~Tower byC, ~~the~~Floor ~~Company~~8, Building 103, Huizhongli, Chaoyang District, Beijing, China.

~~The transaction~~Participants ~~contemplated~~in by the Purchase Agreement constitutes a related-party transaction. On May 18, 2026, the audit committee of the Board (the “Committee”) reviewed the Purchase Agreement and the proposed issuance and sale of the Shares to the Purchaser, including potential conflicts of interest, and approved the Purchase Agreement and the transaction contemplated therein. The Committee determined that the issuance and sale of the Shares to the Purchaser for the aggregate purchase price of US$720,000 is fair and reasonable to the Company and its shareholders and that the negotiations were conducted on an arm’s-length basis. The transaction contemplated by the Purchase Agreement is expected to close on or about May 19, 2026.Solicitation

~~Immediately following~~The ~~the~~Company ~~closing~~and its board of directors (the ~~transaction~~“Board”) ~~contemplated~~and byexecutive officers may be deemed to be participants in the ~~Purchase~~solicitation ~~Agreement,~~of proxies from the ~~Purchaser~~shareholders ~~will~~of ~~beneficially~~the ~~own~~Company ~~40,690,800~~in ~~Class B~~connection ~~ordinary~~with ~~shares,~~the ~~representing~~Extraordinary ~~approximately~~General 83Meeting of Shareholders.~~83%~~ Information regarding certain directors and executive officers of the ~~aggregate~~Company ~~voting~~is ~~power~~available ofin the Company’s ~~outstanding~~documents ~~ordinary~~filed ~~shares~~with or submitted to the SEC. Other information regarding the participants in the proxy solicitation and descriptions of their direct and indirect interests, by security holdings or otherwise, are set forth in the Notice filed herewith.

The foregoing description of the Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is furnished as Exhibit 10.1 to this Report on Form 6-K and incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.		Description ~~of Exhibit~~
10.1		Form of Securities Purchase Agreement
99.1		Notice of Extraordinary General Meeting of Shareholders and Proxy Statement
99.2		Form of Proxy Card

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~Haoxi Health Technology Limited~~	Haoxi Health Technology Limited
Date: May 19, 2026	By:	/s/ Zhen Fan
Date: May 21, 2026		By:	/s/ Zhen Fan
	~~Name:~~	~~Zhen Fan~~Name:	Zhen Fan
	~~Title:~~	~~Chief Executive Officer~~Title:	Chief Executive Officer and Chairman

Filing Compare · Haoxi Health Technology Ltd